ERBB2 and gastric cancer: This review first summarizes the history of major clinical trials of HER2-targeted therapy for advanced gastric cancer, then lists the difficulties encountered in HER2-targeted therapy for gastric cancer, focusing on the promising novel anti-HER2 agent trastuzumab deruxtecan, and finally summarizes ongoing the clinical trials of novel anti-HER2 therapy.